{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:55:07Z","timestamp":1784778907006,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.euroneuro.2012.05.001","type":"journal-article","created":{"date-parts":[[2012,5,26]],"date-time":"2012-05-26T15:32:01Z","timestamp":1338046321000},"page":"118-125","source":"Crossref","is-referenced-by-count":21,"title":["Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"23","author":[{"given":"Karla","family":"Soares-Weiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"B\u00e9chard-Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howard Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Ascher-Svanum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2012.05.001_bib3","first-page":"1","article-title":"A systematic review of atypical antipsychotic drugs in schizophrenia Health","volume":"7","author":"Bagnall","year":"2003","journal-title":"Technol. Assessment"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/JCP.0b013e3180582426","article-title":"All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis","volume":"27","author":"Beasley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib5","series-title":"Introduction to meta-analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/ps.2008.59.5.476","article-title":"Datapoints: did CATIE influence antipsychotic use?","volume":"59","author":"Citrome","year":"2008","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib8","series-title":"Patient compliance in medical practice and clinical trials","author":"Cramer","year":"1991"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4088\/JCP.v68n0801","article-title":"Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder","volume":"68","author":"Dunayevich","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.295.14.1645","article-title":"Constraints on publication rights in industry-initiated clinical trials","volume":"295","author":"Gotzsche","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1740774506069153","article-title":"Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors","volume":"3","author":"Haahr","year":"2006","journal-title":"Clin. Trials"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib1","doi-asserted-by":"crossref","unstructured":"Higgins, J.P.T., Green, S. (Eds.), 2008. Cochrane Handbook for Systematic Reviews of Interventions, first ed. John Wiley and Sons Ltd., Chichester.","DOI":"10.1002\/9780470712184"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib16","doi-asserted-by":"crossref","first-page":"s78","DOI":"10.1192\/bjp.191.50.s78","article-title":"Measurement of long-term outcomes in observational and randomised controlled trials","volume":"191","author":"Hodgson","year":"2007","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2008.540","article-title":"Translating scientific opportunity into public health impact: a strategic plan for research on mental illness","volume":"66","author":"Insel","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib18","series-title":"Risperidone versus olanzapine for schizophrenia, cochrane database of systematic reviews","author":"Jayaram","year":"2006"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib19","first-page":"8","article-title":"Effectiveness of second generation antipsychotics: a systematic review of randomized trials","author":"Johnsen","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib24","first-page":"1","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","author":"Leucht","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1741-7015-3-21","article-title":"Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs","volume":"3","author":"Liu-Seifert","year":"2005","journal-title":"BMC Med."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2012.05.001_bib29","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/schbul\/sbn019","article-title":"Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment","volume":"35","author":"Parks","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2012.05.001_bib32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4088\/JCP.v62n0906","article-title":"Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods","volume":"62","author":"Simpson","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.euroneuro.2012.05.001_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00127-005-0838-9","article-title":"Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network","volume":"40","author":"Zarin","year":"2005","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12001204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X12001204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:50:35Z","timestamp":1542934235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X12001204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0924977X12001204"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2012.05.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}